160 related articles for article (PubMed ID: 20361359)
1. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer.
Nurgalieva Z; Liu CC; Du XL
Med Oncol; 2011 Sep; 28(3):716-25. PubMed ID: 20361359
[TBL] [Abstract][Full Text] [Related]
2. Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer.
Nurgalieva Z; Liu CC; Du XL
Int J Gynecol Cancer; 2009 Nov; 19(8):1314-21. PubMed ID: 20009883
[TBL] [Abstract][Full Text] [Related]
3. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer.
Nurgalieva Z; Xia R; Liu CC; Burau K; Hardy D; Du XL
Am J Ther; 2010; 17(2):148-58. PubMed ID: 19417586
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
8. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
[TBL] [Abstract][Full Text] [Related]
9. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
10. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy.
Baxter NN; Durham SB; Phillips KA; Habermann EB; Virning BA
J Am Geriatr Soc; 2009 Mar; 57(3):403-11. PubMed ID: 19278395
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
Liutkauskiene S; Grizas S; Jureniene K; Suipyte J; Statnickaite A; Juozaityte E
BMC Cancer; 2018 Apr; 18(1):453. PubMed ID: 29678165
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer.
Hershman D; Jacobson JS; McBride R; Mitra N; Sundararajan V; Grann VR; Neugut AI
Gynecol Oncol; 2004 Aug; 94(2):540-9. PubMed ID: 15297201
[TBL] [Abstract][Full Text] [Related]
13. Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer.
Li S; Liu J; Virnig BA; Collins AJ
Breast Cancer Res Treat; 2017 Feb; 161(3):515-524. PubMed ID: 27933451
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
15. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
Hurria A; Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Howard J; Hudis C
Drugs Aging; 2005; 22(9):785-91. PubMed ID: 16156682
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of relative factors of bone marrow suppression after chemotherapy with carboplatin and paclitaxel on the patients with ovarian cancer].
Ding D; Kong WM
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):188-92. PubMed ID: 21575452
[TBL] [Abstract][Full Text] [Related]
17. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
18. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
19. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
Shpall EJ; Jones RB; Bast RC; Rosner GL; Vandermark R; Ross M; Affronti ML; Johnston C; Eggleston S; Tepperburg M
J Clin Oncol; 1991 Jan; 9(1):85-93. PubMed ID: 1985173
[TBL] [Abstract][Full Text] [Related]
20. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]